Gaia

Researchers are evaluating the safety, tolerability, and effectiveness of BNT113 combined with pembrolizumab compared to pembrolizumab alone as a first treatment for patients with unresectable recurrent or metastatic head and neck squamous cell carcinoma HNSCC that tests positive for human papillomavirus 16 HPV16 and expresses the protein PD-L1. This Phase IIIII trial includes patients whose tumors have a combined positive score of 1 or higher for PD-L1. The study is designed to generate important safety and efficacy data for these treatments in this patient group. The trial consists of two parts Part A is a non-randomized safety run-in phase to confirm the safety and tolerability of BNT113 with pembrolizumab. Part B is a randomized phase comparing BNT113 combined with pembrolizumab versus pembrolizumab alone. Treatments are given by intravenous injection or infusion. Patients may receive treatment for up to 24 months. An optional pre-screening phase allows tumor samples to be tested centrally for HPV16 DNA and PD-L1 expression before entering the main trial. Participants will undergo regular assessments including monitoring for treatment-emergent adverse events, overall survival, and progression-free survival for up to 48 months. Researchers will also measure response rates and duration, disease control, and any dose adjustments due to side effects. Patients provide tumor tissue samples before treatment and are monitored closely throughout the study period. The trial aims to collect comprehensive data on safety, treatment effects, and patient outcomes over this extended follow-up.

Researchers are evaluating the medication VH4524184 for treating adults with HIV-1 who have never received treatment before. The study compares two doses of VH4524184, each combined with emtricitabine and tenofovir alafenamide FTCTAF, against a standard treatment of dolutegravir and lamivudine DTG3TC. This phase 2b trial aims to provide data on the long-term antiviral effects and appropriate dosing of VH4524184 for future studies. Participants are randomly assigned to receive either a low or high daily dose of VH4524184 combined with FTCTAF for 12 months, or the standard DTG3TC treatment daily for 24 months. Those on VH4524184 may continue with a selected dose plus FTCTAF from 12 to 24 months. All medications are taken orally, and the study is open-label, meaning participants and researchers know which treatment is given. During the study, participants will undergo regular assessments including blood tests to measure HIV-1 RNA levels and CD4 T-cell counts, monitoring for side effects, and measuring drug concentrations in the blood. The primary outcome is the percentage of participants achieving HIV-1 RNA suppression below 50 copiesmL at 12 months. Safety and maintenance of viral suppression will also be tracked through month 24. The total participation can last up to two years, with ongoing evaluations to understand long-term treatment effects.

Researchers are assessing how the drug rupatadine 10 mg and its active metabolites behave in the bodies of participants with kidney problems compared to those with normal kidney function. The study focuses on the drugs pharmacokinetics how it is absorbed, distributed, metabolized, and excreted, its tolerability, and safety. This open-label, non-randomized study includes adult participants with varying degrees of renal impairment and matched controls without kidney issues. Participants will receive a single 10 mg dose of rupatadine after fasting overnight. The study involves a Screening period up to 28 days before dosing, a Baseline evaluation one day before dosing, a dosing day, and an End of Study visit occurring 8 days after dosing for those with normal kidney function and 12 days for those with renal impairment. Blood samples for drug level measurements and safety assessments will be collected frequently during the study, with participants staying at the clinic from one day before dosing until 24 hours after dosing. Participants will undergo various assessments including blood draws to monitor drug levels over time and safety evaluations such as vital signs, ECGs, and laboratory tests. The study will measure detailed pharmacokinetic parameters like peak plasma concentration, half-life, and clearance of rupatadine and its metabolites. The total participation time is up to approximately 40 days, covering all study visits and assessments.